Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Dopad podávání EV/P v různou denní dobu na objektivní míru odpovědi u dospělých s pokročilým karcinomem močového měchýře (Chrono-EVP)

29. září 2026 aktualizováno: Guliz Ozgun

CHRONO-EVP: Časově závislé podávání enfortumabu vedotinu a pembrolizumabu (EV/P) u pokročilého karcinomu močového měchýře

The goal of this clinical trial is to learn if the timing of treatments plays a role in how effective the standard-of-care drugs enfortumab vedotin and pembrolizumab (EV/P) works to treat adults with advanced bladder cancer. The trial will also learn if time-of-day reduces EV/P side-effects.

Researchers will compare EV/P given in the morning (before 11:30am) vs in the afternoon (after 1:30pm), to see if circadian rhythm effects how EV/P works to treat advanced bladder cancer.

Participants will be randomized in Arm A or Arm B to receive drugs EV/P either in the morning (Arm A) or afternoon (Arm B) as part of their standard-of-care treatment for advanced bladder cancer. Participants will:

  • Visit the clinic either in the morning (Arm A) or afternoon (Arm B) to receive EV/P treatment as part of their regular medical care for advanced bladder cancer
  • Frequency of visits will follow standard-of-care guidelines
  • Participants will be followed-up by the study team for up to 24 months.

Přehled studie

Postavení

Zatím nenabíráme

Typ studie

Intervenční

Zápis (Odhadovaný)

224

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • British Columbia
      • Abbotsford British Columbia, British Columbia, Kanada, V2S 0C2
        • BC Cancer - Abbotsford
        • Kontakt:
      • Kelowna, British Columbia, Kanada, V1Y 5L3
        • BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)
        • Kontakt:
      • Surrey, British Columbia, Kanada, V3V 1Z2
        • BC Cancer - Surrey
        • Kontakt:
      • Vancouver, British Columbia, Kanada, V5Z 4E6
        • BC Cancer - Vancouver Cancer Centre
        • Kontakt:
      • Victoria, British Columbia, Kanada, V8R 6V5

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Participants must meet all of the following inclusion criteria to be eligible for participation in this trial:

    1. Age 18 or older
    2. Able to provide informed consent
    3. Histologically confirmed advanced urothelial cancer
    4. Eligible for standard-of-care EV/P regimen
    5. Measurable disease per RECIST 1.1
    6. ECOG performance status 0-2
    7. Ability to adhere to scheduled infusion times (Before 11:30 a.m. or after 1:30 pm) Waivers to the inclusion criteria will NOT be allowed.

Exclusion Criteria:

  • Participants who meet any of following exclusion criteria will not be eligible for participation in this trial:

    1. Non-urothelial histology or mixed histology with predominant non-urothelial components
    2. Concurrent malignancy requiring active systemic therapy, unless disease-free for at least 2 years
    3. Inability to comply with protocol-specified infusion timing for at least the first 3 months
    4. Night shift workers
    5. Clinical evidence of new or enlarging brain metastasis or carcinomatous meningitis
    6. Known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial
    7. Patients who have traveled across ≥2 time zones within the past 14 days prior to randomization will be excluded, due to potential disruption of circadian rhythms (jet lag), which may affect chronotherapy-related endpoints.
    8. Patients with a clinically diagnosed sleep disorder, including but not limited to insomnia, obstructive sleep apnea, restless leg syndrome, or circadian rhythm sleep-wake disorders, that is moderate to severe, untreated, or poorly controlled, will be excluded.

Waivers to the exclusion criteria will NOT be allowed.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Aktivní komparátor: Arm A: Morning EV/P Treatment

Participants will receive standard-of-care therapy (Ev/P) administered in the morning (before 11:30am).

Participants will receive EV/P as part of their standard-of-care therapy administered either in the morning (Arm A) or afternoon (Arm B), as determined by randomization.

Aktivní komparátor: Arm B: Afternoon EV/P Treatment

Participants will receive standard-of-care therapy (EV/P) administered in the afternoon (after 1:30pm).

Participants will receive EV/P as part of their standard-of-care therapy administered either in the morning (Arm A) or afternoon (Arm B), as determined by randomization.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Objective response rate in in time-of-day administration of EV/P treatment
Časové okno: From enrollment to end of follow-up at 24-months.

Objective response rate (ORR) will be determined by proportion of patients achieving a complete or partial response as assessed by RECIST v1.1 criteria, confirmed by central review or investigator assessment. Tumor assessments will be performed as standard of care (typically every 12 weeks), and best overall response prior to disease progression will be used for ORR determination.

From enrollment to end of follow-up at 24-months.

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Assess treatment-related tolerability and toxicity differences
Časové okno: From enrollment to the end of follow-up at 24-months.

Differences in steroid use (yes/no) for the management of treatment-related toxicity, treatment interruptions (yes/no) due to treatment-related toxicity, and treatment discontinuations (yes/no) due to treatment-related toxicity will be used as surrogate safety outcomes, as comprehensive adverse event documentation is beyond the scope of this pragmatic clinical trial. The study seeks to determine whether treatment administration at a predefined time of day is associated with differences in the need for toxicity-related clinical interventions. Given that the relevant adverse events are well characterized in the existing literature, the focus of this study is on comparative safety between groups using these surrogate measures rather than on detailed characterization of individual adverse events.

From enrollment to the end of follow-up at 24-months.
Immune Profiling
Časové okno: At 4 time points: Baseline, 1-day post first cycle of treatment, 3 weeks into treatment and 12 weeks into treatment

Immune cell populations will be characterized from the blood samples at baseline (prior to treatment initiation) and at three predefined time points during therapy: 1 day after treatment initiation, 3 weeks into treatment, and 12 weeks into treatment. Cytometry by time-of-flight (CyTOF) will be used to comprehensively profile immune cell populations allowing for high-dimensional assessment of immune cell composition and activation states across treatment timing groups.

At 4 time points: Baseline, 1-day post first cycle of treatment, 3 weeks into treatment and 12 weeks into treatment
Bulk RNA sequencing (RNA-seq)
Časové okno: At 4 time points: Baseline, 1-day post first cycle of treatment, 3 weeks into treatment and 12 weeks into treatment

Bulk RNA sequencing (RNA-seq) will be performed to comprehensively characterize global gene expression profiles and to evaluate time-of-day-associated differences in immune-related transcriptional signatures. This approach will enable the identification of circadian variation in gene expression and provide insight into temporal regulation of immune pathways in response to treatment.

At 4 time points: Baseline, 1-day post first cycle of treatment, 3 weeks into treatment and 12 weeks into treatment
Cytokine and chemokine analyses
Časové okno: At 4 time points: Baseline, 1-day post first cycle of treatment, 3 weeks into treatment and 12 weeks into treatment

Plasma will be isolated for cytokine and chemokine analyses to assess systemic immune signaling and inflammatory profiles. Quantitative evaluation of circulating cytokines and chemokines will provide insight into treatment- and time-dependent changes in immune activation, inflammation, and immune regulation, complementing cellular and transcriptional immune profiling.

At 4 time points: Baseline, 1-day post first cycle of treatment, 3 weeks into treatment and 12 weeks into treatment
Evaluate Progression-Free Survival in time-of-day administration of EV/P
Časové okno: From enrollment to end of follow-up at 24-months.

Progression-free Survival (PFS) will be determined by time of randomization to radiographic progression or death from any cause, whichever occurs first.

From enrollment to end of follow-up at 24-months.
Assess Overall-Survival in time-of-day administration of EV/P
Časové okno: From enrollment to the end of follow-up at 24-months.

Overall-survival (OS) is defined as the time from randomization to death from any cause. The analysis will compare OS curves between study arms and estimate 2-year OS rates for each group.

From enrollment to the end of follow-up at 24-months.
Evaluate the Time-to-Treatment Failure in time-of-day administration of EV/P
Časové okno: From enrollment to the end of follow-up at 24-months.

Time to treatment failure (TTF) is determined by assessing time from treatment initiation to treatment discontinuation for any reason, including disease progression, unacceptable toxicity, patient withdrawal, or death, capturing both treatment efficacy and tolerability.

From enrollment to the end of follow-up at 24-months.
Assess quantitative changes in ctDNA Kinetics of time-of-day administration of EV/P
Časové okno: Baseline, 3 weeks, and 12-weeks.

Quantitative changes in circulating tumour DNA (ctDNA) levels will be collected and measured at baseline, post-cycle 1 (~3 weeks), and at post-cycle 4 (~12 weeks) at first radiographic assessment, with correlation to response and survival outcomes.

Baseline, 3 weeks, and 12-weeks.
Circulating Tumor DNA (ctDNA) Analyses
Časové okno: At 3 time points: Baseline, 3 weeks into treatment and 12 weeks into treatment

Circulating tumor DNA (ctDNA) analyses will be performed on plasma samples collected at baseline (prior to treatment initiation), 3 weeks into treatment, and 12 weeks into treatment. ctDNA dynamics will be evaluated to assess molecular response to therapy, including changes in ctDNA levels and ctDNA clearance rates over time. Comparisons will be made between treatment administration at different times of day to determine whether timing of therapy is associated with differences in ctDNA kinetics, clearance rates, and early molecular response.

At 3 time points: Baseline, 3 weeks into treatment and 12 weeks into treatment

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. listopadu 2026

Primární dokončení (Odhadovaný)

1. prosince 2030

Dokončení studie (Odhadovaný)

1. prosince 2032

Termíny zápisu do studia

První předloženo

8. prosince 2025

První předloženo, které splnilo kritéria kontroly kvality

7. ledna 2026

První zveřejněno (Aktuální)

16. ledna 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

1. října 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

29. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NEROZHODNÝ

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit